Navigation Links
Genetic function discovered that could offer new avenue to cancer therapies
Date:2/3/2014

CORVALLIS, Ore. Researchers at Oregon State University have discovered a genetic function that helps one of the most important "tumor suppressor" genes to do its job and prevent cancer.

Finding ways to maintain or increase the effectiveness of this gene called Grp1-associated scaffold protein, or Grasp could offer an important new avenue for human cancer therapies, scientists said.

The findings were just published in Photochemical and Photobiological Sciences, a journal of the Royal Society of Chemistry, by researchers from OSU and Oregon Health & Science University. The work was supported by the National Institute of Environmental Health Sciences.

The Grasp gene was studied in the skin of mice in this research, but is actually expressed at the highest levels in the brain, heart and lung, studies have shown. It appears to play a fundamental role in the operation of the p53 tumor suppressor gene, which is a focus of much modern cancer research.

The p53 gene is involved in repair of DNA damage and, if the damage is too great, causing a mutated cell to die before it can cause further problems, up to and including cancer. Dysfunction of p53 genetic pathways have been linked to more than half of all known cancers - particularly skin, esophageal, colon, pancreatic, lung, ovarian, and head and neck cancers.

"DNA mutations occur constantly in our bodies just by ordinary stresses, something as simple as exposure to sunlight for a few seconds," said Mark Leid, professor of pharmacology and associate dean for research in the OSU College of Pharmacy, and one of the lead authors on this study.

"Just as constantly, the p53 gene and other tumor suppressors are activated to repair that damage," Leid said. "And in cases where the damage is too severe to be repaired, p53 will cause the apoptosis, or death of the mutated cell. Almost all of the time, when they are working right, these processes prevent the formation of cancers."

But the activity and function of p53 can sometimes decline or fail, Leid said, and allow development of cancer. Promising approaches to cancer therapy are now based on activating or stimulating the p53 protein to do its job.

The new study has found that the Grasp gene is significantly involved in maintaining the proper function of p53. When "Grasp" is not being adequately expressed, the p53 protein that has entered the cell nucleus to either repair or destroy the cell comes back out of the nucleus before its work is finished.

"It appears that a primary function of Grasp is to form sort of a halo around the nucleus of a damaged skin cell, and act as kind of a plug to keep the p53 cell inside the nucleus until its work is done," Leid said. "A drug that could enhance Grasp function might also help enhance the p53 function, and give us a different way to keep this important tumor suppressor working the way that it is supposed to.

"This could be important," he said.

OSU experts created laboratory mice that lacked the Grasp gene, and so long as the mice were reared in a perfect environment, they developed normally. But when they were exposed to even a mild environmental stress ultraviolet light similar to moderate sun exposure they began to develop cellular abnormalities much more rapidly than ordinary mice. Most significantly, mutated skin cells did not die as they should have.

In normal mice, the same moderate light exposure caused a rapid increase in expression of the Grasp gene, allowing the p53 protein to stay in the nucleus and normal protective mechanisms to do their work.

Most current cancer therapies related to the p53 tumor suppression process are directed toward activating the p53 protein, Leid said. A therapy directed toward improving the Grasp gene function would be a different approach toward the same goal, he said, and might improve the efficacy of treatment.


'/>"/>
Contact: Mark Leid
mark.leid@oregonstate.edu
541-737-5809
Oregon State University
Source:Eurekalert

Related biology news :

1. Dartmouth researchers develop new tool to identify genetic risk factors
2. Genetics Society of America selects 5 geneticists to receive societys 2014 Awards
3. David Allis, pioneer in epigenetics, to receive prestigious Japan Prize
4. 23andMe helps identify 11 new genetic associations for asthma-with-hay fever
5. Scientists find genetic mechanism linking aging to specific diets
6. Genomics for judges: Educating Illinois judges on how genetic info impacts court decisions
7. Complimentary press registration now open for ACMG 2014 Annual Clinical Genetics Meeting
8. Toddlers aggression is strongly associated with genetic factors
9. Important discovery for the diagnosis of genetic diseases
10. First comprehensive test to detect genetic modification in food
11. Multiple myeloma study uncovers genetic diversity within tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2016)... 16, 2016   IdentyTechSolutions America LLC , ... and solutions and a cutting-edge manufacturer of software ... is offering seamless, integrated solutions that comprise IDT ... The solutions provide IdentyTech,s customers with combined physical ... from crime and theft. "We are ...
(Date:12/15/2016)... ... Markets has announced the addition of the "Global Military Biometrics Market ... the global military biometrics market to grow at a CAGR of 7.5% ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
(Date:12/8/2016)... Research Future published a half cooked research report on Mobile Biometric ... Market is expected to grow over the CAGR of ~35% during ... ... Mobile Biometric Security and Service Market is increasing at a ... security from unwanted cyber threats. The increasing use of mobile device ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ), a ... live webcast of its Annual Meeting of Shareholders on Tuesday, January ... can be accessed from the BD corporate website at http://www.bd.com/investors/ ... ... BD is a global medical technology company that is ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 According to ... Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, ... market is expected to reach USD 739.9 Million by 2021 from USD 557.1 ... Continue Reading ... MarketsandMarkets Logo ...
(Date:1/18/2017)... 2017 Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced that Dr. ... of Applied BioMath, will present at the next ... Meeting on Thursday January 19, 2017 at the ... MA.   Dr. Burke,s talk "Quantitative Modeling and Simulation ...
(Date:1/18/2017)... ... ... Executive search firm Slone Partners proudly supports the SCOPE ... of the clinical trials segment. Hosted in Miami, this conference brings together renowned ... , As executive talent specialists in the industries central to clinical trials, ...
Breaking Biology Technology: